Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sacituzumab govitecan + datopotamab deruxtecan + sacituzumab tirumotecan
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This entry refers to a collective grouping of three distinct TROP2-targeted antibody-drug conjugates (ADCs) being evaluated in a clinical study at Fudan University. Each agent consists of a monoclonal antibody targeting the Tumor-Associated Calcium Signal Transducer 2 (TROP2) protein, linked to a cytotoxic topoisomerase I inhibitor payload. **Sacituzumab govitecan** (Trodelvy) utilizes an SN-38 payload; **datopotamab deruxtecan** (Dato-DXd) utilizes a deruxtecan (DXd) payload; and **sacituzumab tirumotecan** (also known as SKB264 or MK-2870) utilizes a proprietary belotecan-derivative payload (KL610015). These agents are being studied in advanced HER2-negative breast cancer to determine if molecular imaging, specifically ^68Ga-TROP2 PET/CT and ^18F-FDG PET/CT, can predict treatment response and clinical outcomes based on in vivo TROP2 expression and metabolic activity.
- Other names
- Dato-DXdsacituzumab tirumotecan-Fudan University-breast cancer
02
Targets
TACSTD2 (Tumor-associated calcium signal transducer 2)
Beyond the preview
Go deeper on sacituzumab govitecan + datopotamab deruxtecan + sacituzumab tirumotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sacituzumab govitecan + datopotamab deruxtecan + sacituzumab tirumotecan.